Understanding dopaminergic dose reduction following STN-DBS: mediation analysis.
Lanore A, Houot M, Basset A, Bendetowicz D, Menon PJ, Bardinet E, Fernandez Vidal S, Cornillault J, Karachi C, Navarro S, Ihle J, Eusebio A, Giordana C, Rouaud T, Drapier S, Guehl D, Marques A, Hubsch C, Jarraya B, Benatru I, Thobois S, Hopes L, Maltete D, Rascol O, Tir M, Moreau C, Tranchant C, Rolland AS, Devos D, Corvol JC, Grabli D, Hainque E; PREDISTIM study group.
Lanore A, et al.
BMJ Neurol Open. 2026 Jan 16;8(1):e001427. doi: 10.1136/bmjno-2025-001427. eCollection 2026.
BMJ Neurol Open. 2026.
PMID: 41561678
Free PMC article.